ClinicalTrials.gg
RecruitingNCT07508553TWINBONEUpdated Apr 2, 2026

Comparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric Examination

An interventional study of bone densitometric examination using REMS technology and questionnaires in Osteoporosis, Pregnancy and Twin Pregnancy, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 30 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
30 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Osteoporosis with a site in Italy — 21 open to participants now, 25 under way, none of them phase 3. Osteoporosis · Italy.

Planned enrollment
20th of 35
100 · median 120
Started
2025
with 5 others
No phase
16 of 60
7 open now
Primary completion
2026-12
later than 16 of 24 live
Registered
56th of 60
by date
Lead sponsor
3 of 60
Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Among the 60 studies in Osteoporosis with a site in Italy, this one is the 20th largest by planned enrollment of the 35 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 56th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

21 of the 60 studies in Osteoporosis with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 30 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Osteoporosis with a site in Italy, or all of them as a file.
02

Study summary

This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of:

  • two specific questionnaires developed by the Fragility Fracture Observatory (OFF), and
  • a bone densitometric examination using REMS technology, performed between the 35th and 41st week of gestation.

Primary objective:

  • To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with singleton pregnancies and women with dichorionic and monochorionic twin pregnancies.

Secondary objectives:

  • Evaluate the relationship between bone mineral density (BMD) values and maternal clinical and historical parameters, such as age, body mass index (BMI), and obstetric and medical history.
  • Evaluate the association between BMD values and scores obtained from validated questionnaires administered to investigate fracture risk and bone health-related quality of life in women with singleton and twin pregnancies.
Read the detailed description

Upon enrollment, gestational history, maternal clinical conditions, drug therapy, demographic and anthropometric parameters will be recorded, and specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. These questionnaires aim to assess all risk factors that could lead patients to have a fracture during pregnancy and to evaluate both dietary habits (specifying the type of food with high, medium and low calcium content with relative portions and frequencies) and adherence to the Mediterranean diet (determining, based on the total score, whether the dietary calcium intake is sufficient to support the physiological adaptation of the pregnant woman, who must provide adequate amounts of calcium for the development of the fetal skeleton and the correct growth of the newborn during breastfeeding).

The first questionnaire is divided into two sections: one specifically for "calcium intake" and the other dedicated to assessing the woman's eating habits (Predimed Questionnaire) during pregnancy, which measures portion sizes and the frequency of nutrient intake through food and beverages.

The second questionnaire, AFEF (Fracture Risk Algorithm for Women of Childbearing Age), specifically assesses fracture risk during pregnancy. It collects anthropometric information (weight and height), medical history and personal and family medical history, lifestyle (number of cigarettes smoked daily), and any therapies undertaken before and during pregnancy.

An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester checkup.

The importance of using REMS ultrasound lies in its complete absence of ionizing radiation, ease of use, and rapid scanning. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows for the assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures. All of this makes this method absolutely compatible and optimal for routine monitoring of bone health and fracture risk in women during pregnancy.

The objectives of the REMS ultrasound technology are:

  1. To obtain a quantitative and qualitative assessment of bone status at the proximal femur level in all patients enrolled in the study, stratifying them into two groups based on the BMD values obtained (normal and reduced).
  2. To evaluate, using the REMS-based Fragility Score (FS), the risk factors associated with changes in bone fragility, and to identify the cut-off for the FS measured at the femoral neck specifically for pregnant women.

The EchoStation device (manufactured by Echolight Spa) consists of a medical-grade cart, which houses a panel PC, a medical-grade keyboard and mouse, a main unit, and a convex probe operating at a nominal frequency of 3.5 MHz. The EchoStudio software, integrated into the EchoStation device, dedicated to assessing bone health, allows for the automatic calculation of the same diagnostic parameters provided by a DEXA scan (Bone Mineral Density (BMD), T-score, and Z-score) from unfiltered ultrasound radiofrequency signals acquired during an ultrasound scan of a reference anatomical specimen (femoral neck). The ultrasound signals of the bone region in question are automatically processed and compared with reference spectral models previously derived from healthy and osteoporotic patients in order to assess the subject's bone mineral density; and with previously derived reference spectral models from patients with and without fractures to assess bone fragility and related fracture risk using the innovative FS parameter.

This approach, unlike conventional ultrasound, maximizes the information gathered from the acquired signals, while the reconstructed B-mode ultrasound images serve as a guide for the correct identification of the bone being examined. The simultaneous acquisition of multiple ultrasound signals for each frame is integrated with the ultrasound imaging, which also serves as a guide for identifying the region of interest (ROI) within the bone being examined, providing a solid and reliable statistical basis for subsequent analyses.

Women between the 35th and 41st week of gestation (inclusive) will undergo ultrasound examination of the proximal femur using an EchoStation ultrasound system (Echolight Spa, Lecce, Italy) with a convex probe operating at a nominal frequency of 3.5 MHz. Trained operators will follow a standard procedure. Specifically, a 40-second software-guided ultrasound scan will be performed with the ultrasound probe positioned at the head-neck axis of the femur. The probe will be positioned parallel to the long axis of the femur, and the transducer focus and scan depth will be appropriately set to place the femoral neck interface in the focal zone of the beam and in the central portion of the image. The software will then automatically analyze the unfiltered ultrasound signals, identifying the bone interface and ROI; the resulting signals will be processed and, after this automatic process, the diagnostic report will be produced.

03

Conditions studied

  • Osteoporosis
  • Pregnancy
  • Twin Pregnancy

Browse trials for

Keywords

  • pregnancy
  • twin pregnancy
  • bone mineral density
  • ultrasound densitometry
04

Who can participate

Ages eligible
30 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Willingness to participate in the study and ability to complete the study questionnaires
  3. Women between 35 and 41 weeks of gestational age at the time of study inclusion
  4. Singleton or twin pregnancy (dichorionic or monochorionic)
  5. Age between 30 and 45 years at the time of study recruitment
  6. No history of recent or previous bone fractures or traumatic fractures, and no motor disabilities (in the mother).
  7. Absence of a diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS).
  8. No intake of vitamin D or other medications during pregnancy.
  9. Absence of current or previous conditions that could potentially interfere with bone metabolism (e.g., thyroid, kidney, or liver disease).
  10. Women of normal weight or with class I obesity ( between 18.5 and 34).

Exclusion criteria

EXCLUSION CRITERIA

Patients will not be included in the study if at least one of the following exclusion criteria is met:

  1. Failure to sign the form
  2. Poor compliance and/or inability to complete the study questionnaires
  3. Women with previous or newly diagnosed comorbidities during pregnancy
  4. Age \<30 and >45 years
  5. Previous diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)
  6. \<18.5 or >34
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    singleton pregnancy

    Women in physiological pregnancy between the 35th and 41st week, with a single pregnancy

    Device: bone densitometric examination using REMS technology · Other: questionnaires

  • Experimental
    Twin pregnancy

    Women in physiological pregnancy between the 35th and 41st week, with a single pregnancy

    Device: bone densitometric examination using REMS technology · Other: questionnaires

Interventions

  • Devicebone densitometric examination using REMS technology

    An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester check-up. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures.

  • Otherquestionnaires

    Specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. Their purpose is to assess all risk factors that could lead to fractures during pregnancy, as well as to evaluate both dietary habits and adherence to the Mediterranean diet

06

What researchers measure

Primary outcomes

  1. BMD differences between singleton and twin pregnancies

    To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with a singleton pregnancy and women with dichorionic and monochorionic twin pregnancies.

    Time frame: From enrollment through delivery, an average of six weeks

Secondary outcomes

  1. BMD values and maternal clinical parameter

    Evaluation of the correlation between bone mineral density (BMD), measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and the following maternal clinical parameters: body mass index (BMI, kg/m²) maternal age (years) weight gain during pregnancy (kg) The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution).

    Time frame: From enrollment through delivery, an average of six weeks

  2. Correlation between bone mineral density (DEXA, g/cm²) and validated questionnaire scores (calcium intake, PREDIMED, AFEF)

    Evaluation of the correlation between bone mineral density (BMD) values, measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and: * daily dietary calcium intake, assessed using a dedicated questionnaire and expressed in mg/day * adherence to the Mediterranean diet, assessed using the PREDIMED questionnaire and expressed as a total score * individual risk, assessed using the AFEF questionnaire and expressed as a total score The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution)

    Time frame: From enrollment through delivery, an average of six weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 12 months is below that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Apr 2, 2026
StartActual
Dec 23, 2025
Primary completionEst.
Dec 23, 2026
CompletionEst.
Dec 23, 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07508553
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Dec 23, 2025
Primary completion
Dec 23, 2026 (estimated)
Completion
Dec 23, 2027 (estimated)
Last update
Apr 2, 2026

Study contacts

Tullio Ghi
Contact
tullio.ghi@policlinicogemelli.it
0630155989
Tullio Ghi
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion